Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01490658 · ClinicalTrials.gov registry record · Phase 1
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 93
- Enrollment target
NCT01490658 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 93 participants.
The verdict
NCT01490658, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 93 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to compare repaglinide and metformin as co-administered tablets and as a combination tablet.
Interventions
- DRUG metformin
- DRUG repaglinide
- DRUG repaglinide and metformin combination tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2006-06 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01490658
The ClinicalTrials.gov registry entry for NCT01490658 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which metformin is the first listed.
NCT01490658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01490658 about?
NCT01490658 is a clinical study titled "Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers". This trial is conducted in the United States of America (USA). The aim of this trial is to compare repaglinide and metformin as co-administered tablets and as a combination tablet.
What is the current status of trial NCT01490658?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 2006-06. Estimated completion is 2006-08.
What interventions are being tested in trial NCT01490658?
The interventions under investigation include: metformin (DRUG), repaglinide (DRUG), repaglinide and metformin combination tablet (DRUG).
Who is sponsoring clinical trial NCT01490658?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.